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Protocol
AbstrACt
Introduction Type 2 diabetes (T2D) is increasingly 
contributing to the global burden of disease. Health 
systems in most parts of the world are struggling to 
diagnose and manage T2D, especially in low-income 
and middle-income countries, and among disadvantaged 
populations in high-income countries. The aim of this 
study is to determine the added benefit of community 
interventions onto health facility interventions, towards 
glycaemic control among persons with diabetes, and 
towards reduction in plasma glucose among persons with 
prediabetes.
Methods and analysis An adaptive implementation 
cluster randomised trial is being implemented in two rural 
districts in Uganda with three clusters per study arm, in an 
urban township in South Africa with one cluster per study 
arm, and in socially disadvantaged suburbs in Stockholm, 
Sweden with one cluster per study arm. Clusters are 
communities within the catchment areas of participating 
primary healthcare facilities. There are two study arms 
comprising a facility plus community interventions arm 
and a facility-only interventions arm. Uganda has a third 
arm comprising usual care. Intervention strategies focus 
on organisation of care, linkage between health facility 
and the community, and strengthening patient role in self-
management, community mobilisation and a supportive 
environment. Among T2D participants, the primary 
outcome is controlled plasma glucose; whereas among 
prediabetes participants the primary outcome is reduction 
in plasma glucose.
Ethics and dissemination The study has received 
approval in Uganda from the Higher Degrees, Research 
and Ethics Committee of Makerere University School 
of Public Health and from the Uganda National Council 
for Science and Technology; in South Africa from the 
Biomedical Science Research Ethics Committee of the 
University of the Western Cape; and in Sweden from the 
Regional Ethical Board in Stockholm. Findings will be 
disseminated through peer-reviewed publications and 
scientific meetings.
trial registration number ISRCTN11913581; Pre-results.
strengths and limitations of this study
 ► The Self-Management and Reciprocal learning for 
the prevention and management of Type 2 Diabetes 
adaptive implementation trial will evaluate the added 
benefit of community intervention strategies on type 
2 diabetes outcomes, beyond optimised health facil-
ity strategies in Uganda, South Africa and Sweden, 
exemplifying a low-income, middle-income and 
high-income setting (disadvantaged population), re-
spectively, all facing challenges in tackling the type 
2 diabetes burden.
 ► The intervention we are implementing and evaluat-
ing is built on evidence-based strategies that have 
been contextualised based on formative research 
and collaboration with local and subnational stake-
holders, to ensure acceptability and feasibility for 
scale up.
 ► The study design will allow comparison and recip-
rocal learning on what works and what does not 
across settings.
 ► The adaptive trial design and the monitoring of the 
implementation process allow for the intervention 
to be adapted to the contextual needs and to draw 
lessons for the scale-up implementation in other 
contexts.
 ► As the intervention will be implemented as a pack-
age of intervention elements, we will be unable to 
evaluate the effectiveness of specific intervention 
elements.
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IntroduCtIon 
Type 2 diabetes (T2D) and prediabetes are increasingly 
contributing to the global burden of disease.1 The global 
burden of diabetes in adults >18 years old is projected 
to increase from an estimated 415 million (prevalence of 
8.8%) in 2015 to 642 million (prevalence of 10.4%) by 
2040. The most dramatic change is expected to come 
from the projected increase in the number individuals 
with T2D in Sub-Saharan Africa (SSA) from 14.2 million 
in 2015 to 34.2 million, an increase of more than 100%.2 
Of all individuals with T2D worldwide, 80% live in low-in-
come and middle-income countries (LMICs). There are 
also major differences in the prevalence and access to care 
between immigrants and the general population, espe-
cially in high-income countries (HICs), due to difficul-
ties in integrating migrant population into the receiving 
healthcare system.3 For example, in Canada, immigrants 
from South Asia, Latin America, the Caribbean and SSA 
have a 2–3 times greater risk of developing diabetes than 
their counterparts in the general population.4 
Further, globally the proportion of undiagnosed 
diabetes is high, standing at 46.5%. In high-income 
regions like Europe, of all persons with T2D, 39.3% are 
undiagnosed.2 Low-income countries in Africa have the 
highest prevalence of undiagnosed diabetes, estimated 
at 66.7%.2 Health systems in most parts of the world are 
struggling to diagnose and manage T2D effectively, espe-
cially in LMIC, and among disadvantaged populations in 
high-income countries (d-HIC).
The economic burden of diabetes is very high too. 
Health spending due to diabetes in 2015 was estimated 
at US$5374 per person with diabetes in HICs, compared 
with US$ 401 in LMIC. Compared with HICs, people 
living in LMIC pay a larger out-of-pocket share of health 
expenditure because they have limited access to health 
insurance and publicly available medical services.2
It is clear that T2D is a global burden affecting HICs and 
LMICs in different ways. Whereas evidence for preven-
tion and management is solid from efficacy and imple-
mentation trials,5 6 efforts to contextualise such evidence 
to LMIC or d-HIC are limited. There is a need to identify 
context relevant interventions that can potentially work 
across different income settings, aimed at improving 
the prevention and management of T2D. Further, effec-
tive management of T2D and similar chronic condi-
tions require a multidisciplinary approach beyond the 
biomedical. A multidisciplinary approach focusing on 
the individual, his or her family, community and envi-
ronment and their interlinkages and interdependencies 
is more relevant,7 with added emphasis on self-man-
agement support.8 The content of biomedical care and 
self-management support for people with diabetes has 
been well-elaborated, including guidelines for health 
systems operating in resource limited settings.9 Yet, the 
implementation of contextualised strategies taking into 
account this multidisciplinary approach has been limited.
The project titled ‘A people-centred approach 
through Self-Management and Reciprocal learning for 
the prevention and management of Type-2-Diabetes 
(SMART2D)’ aims at contributing to the implementa-
tion gap highlighted above. Given the global nature of 
the diabetes problem, the project is being implemented 
in three settings comprising three population groups 
namely, a rural population in a LIC (Uganda); an urban 
population in a MIC (South Africa); and an urban, 
socially disadvantaged and mainly immigrant population 
in a HIC (Sweden). The aim of the SMART2D trial is to 
contextualise integrated care comprising health facility 
plus community intervention strategies for prevention 
and management of T2D, informed by an adapted theory 
of change (ToC) and formative research; and to evaluate 
the feasibility and the incremental cost of implementing 
the interventions in an adaptive implementation trial. 
This paper describes the protocol of the implementation 
trial.
MEthods And AnAlysIs
study design
The study was designed as an adaptive implementation 
trial using cluster sampling, with two study arms; an inte-
grated care arm comprising optimal health facility plus 
community intervention strategies versus facility only 
intervention strategies. A cluster is the community within 
the catchment area of the participating health facility. 
Prior to initiation of the trial, the clusters at each of 
the country sites were assigned to the study arms of the 
trial. In Sweden and South Africa, where primary care 
processes are already adequately established based on 
the respective national guidelines for diabetes manage-
ment, we are testing the added benefit of integrated care, 
against facility only care. In Uganda where primary care 
processes for T2D are not yet part of standard of care, the 
trial has three arms: integrated care and facility only care 
as two intervention arms, and usual care (with no inter-
vention) as the control arm.
Context, targeted sites and populations
The trial is being conducted in three settings, reflecting 
three contexts in which health systems are still struggling 
to diagnose and manage T2D effectively. In Uganda, a 
low-income country, the trial is being conducted at nine 
primary healthcare facilities (health centre level III and 
level IV), located in the two rural districts of Iganga and 
Mayuge in the eastern part of the country. These are the 
primary healthcare facilities at which persons with diabetes 
first interface with the healthcare system for diabetes 
care. Health centre level III serves approximately 20 000 
people at subcounty level, with health services including 
outpatient services, normal deliveries, limited in-patient 
care and tuberculosis (TB) treatment. It is headed by a 
clinical officer and has a laboratory that conducts basic 
tests (malaria, urine, blood sugar and TB). Health centre 
level IV is a mini-hospital serving approximately 100 000 
people at county level. It is headed by a medical doctor 
and has nursing officers with diverse skills.
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In South Africa, the trial is being conducted at two 
community health centres (CHCs) in the Khayelitsha 
township in Cape Town in the Western Cape. Both CHCs 
provide primary healthcare, including chronic care 
services, and fall under the provincial authority. The two 
facilities were purposively selected based on their demo-
graphic similarity, catchment areas and exclusion from 
other trials.
In Sweden, the trial is being conducted in two urban 
districts within Stockholm municipality representing 
d-HIC. These are socially disadvantaged suburbs and 
comprise predominantly immigrant communities 
(approximately 56%) and together have a total popula-
tion of about 55 000. Each of the districts is catered to 
by a state-run primary healthcare centre, participating in 
the study. Since the suburbs chosen varied in terms of the 
composition of immigrant groups and the overall socio-
economic status; and the participating health centres 
varied in terms of staff capacity and services; the catch-
ment area of each of the participating health centres 
was divided into zones using postal codes. These zones 
were randomly allocated to primary versus integrated 
care, while being careful to prevent contamination and 
spillover.
Intervention
We developed a ToC to guide phased development 
of the interventions. To optimise contextualisation 
and cross-context lessons, intervention development 
included four phases: (1) literature review on diabetes 
and self-management to inform the development of a 
generic ToC, (2) situation analysis/needs assessment 
with a generic and contextualised topic guide for 
data collection, (3) synthesis of situation analysis in 
each country to identify both local contextualised and 
common needs across contexts and (4) finalisation and 
agreement on a common intervention framework with 
generic strategies and key elements, with contextualised 
health facility and  community intervention strategies 
as the output. Online supplementary file s1 summarises 
the ToC process used.
The primary care intervention comprise two key health 
facility strategies: (1) organisation of care and (2) strength-
ening of the patient role in self-management, each with a 
number of intervention elements. Intervention elements 
are only implemented if they are currently lacking or in 
need of strengthening. For example, Uganda lacks most of 
the elements for both strategies, while Sweden and South 
Africa mainly need strengthening of the patient role. Key 
facility intervention elements under each strategy were 
developed and contextualised for implementation across 
the settings, as described in table 1.
The integrated care interventions include the above 
described health facility strategies and three key 
community strategies, that is: (1) community mobil-
isation, (2) strengthen the supportive environment 
and (3) involving a community extension (ie, linkage 
between facility and community). Similarly, community 
intervention elements were developed and contextual-
ised for implementation across the settings, as described 
in table 2.
Taken together, the integrated care strategies address 
the six pillars of the chronic care edifice as specified 
by the chronic care model,10 that is, (1) community 
resources and policies, (2) healthcare organisation, (3) 
self-management support, (4) delivery system design, (5) 
decision support and (6) clinical information system. 
Figure 1 illustrates the implementation strategy and 
timing of community interventions, as well as the health 
facility interventions.
Participants
Participants are residents within the designated clusters 
at each country site. Individuals are eligible for enrol-
ment if they are: currently residing in, and have resided 
in their respective communities for at least 6 months 
prior to enrolment; aged between 30 and 75 years; have 
no plans of migrating out of the study area over the next 
12 months from the date of enrolment; able to provide 
written informed consent; agree to home visits and 
follow-up contacts as part of study participation; have 
not been previously diagnosed with diabetes for longer 
than 12 months; and have a positive confirmatory test of 
prediabetes or diabetes. Pregnancy and serious mental 
disability are exclusion criteria.
recruitment
A generic recruitment algorithm was developed and 
modified by each site to fit the local context by focusing 
on locally relevant methods and tests. Each site uses 
different strategies to mobilise communities; screen 
potential participants; and recruit those who fulfil the 
criteria as described below.
Uganda
Within each cluster, trained Field Research Assistants 
(FRA) approach households explaining the study to 
household members, and seeking consent for screening 
for possible participation in the study. FRAs seek a 
written pre-eligibility screening informed consent from 
adult members of the household and administer a short 
screening form based on the inclusion criteria listed above 
to consenting adults. An appointment is then made with 
potentially eligible household members to return early 
morning on an agreed date, for a fasting plasma glucose 
(FPG) test. If the first FPG test is at least 6.1 mmol/L, a 
second appointment is made for a repeat FPG test. If the 
second FPG is also at least 6.1 mmol/L, the household 
member is referred to the respective cluster health facility 
for further screening to confirm eligibility. The household 
member is advised to report to the health facility within 
7 days after an overnight fast without exercise or smoking. 
On presentation to the health facility, a third FPG test 
is conducted to confirm eligibility. Eligible subjects are 
classified as having prediabetes if at least two of their FPG 
test results are between 6.1 and 6.9 mmol/L, or as having 
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diabetes if at least two FPG test results are >6.9 mmol/L, 
as illustrated in figure 2 for Uganda.
South Africa
Study investigators conduct a community awareness 
raising campaign in partnership with the local branch of 
a national non-government organisation (NGO) to drive 
participant recruitment. The venue is a central location, 
which draws large numbers of visitors, such as a shop-
ping mall located in close proximity to the study facili-
ties. Awareness campaigners screen consenting adults to 
identify potential trial participants and conduct a random 
plasma glucose (RPG) test. This is followed by referral of 
eligible subjects to the health facility for an FPG, in line 
with the diagnostic criteria of the practical approach to 
care kit (PACK) guidelines for primary care. Subjects with 
a RPG ≥6.1 mmol/L are given a referral note and advised 
to visit their health facility within a week, after an over-
night fast and they are advised to report with no exercise 
or smoking.
Recruitment takes place at the two selected study facil-
ities, when visiting the facility for routine clinical care or 
Figure 1 Flow chart for the SMART2D facility (blue) and community (green) interventions. CC, care companion or healthy 
lifestyle buddy; CLT, community link team; FINDRISC, Finland Diabetes Risk; FPG, fasting plasma glucose; PGM, peer group 
meeting; SMART2D, Self-Management and Reciprocal learning for the prevention and management of Type 2 Diabetes.  
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on referral from the community as per the above outlined 
protocol. Subjects are classified as having diabetes if two 
consecutive FPG tests >6.9 mmol/L, or as having predia-
betes if two consecutive FPG tests are between 6.1 mmol/L 
and 6.9 mmol/L. A third FPG test (tiebreaker) is 
conducted if the first two test results are not consistent to 
classify a subject as either having diabetes or prediabetes 
as illustrated in figure 2 for South Africa. Persons meeting 
the above criteria are invited to participate in the trial.
Sweden
Participants are recruited into the trial through commu-
nity screening and from the participating health centres. 
The research team together with health centres and 
municipalities have identified opportunities and spaces 
in the community to carry out screening activities. Both 
research staff and outreach workers from the munici-
palities are involved in mobilising community members 
and inviting them to participate in the screening, by: (1) 
facilitating access to the target population through local 
NGOs, immigrant associations, religious bodies, such as 
churches and mosques and cafes or other ventures owned 
by immigrant groups and (2) identifying and facilitating 
access to spaces to set up the screening activities such as 
shopping malls, local library, municipality hall or other 
public spaces such as swimming halls.
Community screening activities are carried out by 
the research team on weekdays and weekends using a 
combination of Finland Diabetes Risk (FINDRISC),11 
and haemoglobin A1c (HbA1c) test (both point-of-care 
and laboratory based) using a recruitment algorithm 
summarised in figure 2 for Sweden. All individuals with 
HbA1c values in the diabetes or prediabetes range are 
referred to the health centres to be recruited and enrolled 
into the primary care only arm, or the integrated care 
arm based on the postal code of their area of residence. 
In addition, patients with T2D registered at the partici-
pating health centres who fulfil the inclusion criteria are 
invited by the diabetes nurse (and the implementation 
manager of the research team) through a phone call to 
participate in the study.
Enrolment and baseline measurements
Once eligibility is confirmed, written informed consent 
is obtained, and subjects are enrolled. Trained study 
staff administer a standardised baseline questionnaire to 
obtain basic participant data comprising demographic 
and socioeconomic measures; medical and medica-
tion history; behavioural measures (diet, tobacco use, 
alcohol use, physical activity and foot care); and physical 
measures (weight, height, waist circumference and blood 
pressure).
As the intervention strategies use the principles of 
self-determination theory (SDT),12 the questionnaire 
also collects data on components of the SDT including; 
level of social support the participant is receiving, 
sources of such social support, self-efficacy, autonomy 
support, self-regulation, psychological adjustment, 
quality of life, stress and diabetes knowledge. Further, 
HbA1c test, FPG (Uganda and South Africa only) and 
clinical examination are performed. For participants 
with diabetes, baseline data are collected on out-of-
pocket expenditure, including outpatient costs, hospi-
talisation costs over the past 12 months, and household 
expenditure. At the end of these procedures, partici-
pants are given a pedometer, which they are instructed 
Figure 2 Recruitment algorithm. *FPG and HbA1c values based on WHO recommendation. FINDRISC, Finland Diabetes Risk; 
FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; PoC, point-of-care; T2D, type 2 diabetes. 
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to wear for the next 7 days to record a 7 day number of 
footsteps. Participants return the pedometer after the 
7 days to record the number of steps made. Data are 
collected in a staggered manner to minimise respon-
dent burden. Details of the data collection tools used 
in the study are provided in online supplementary file 
s2. In addition, a process evaluation guide checklist has 
been developed to measure the delivery of the interven-
tion. It is inspired by the Reach, Effectiveness, Adoption, 
Implementation and Maintenance (RE-AIM) frame-
work13 and implementation fidelity framework14 and 
has a number of common elements for all sites, that are 
linked to the most important intervention strategies in 
the facility and the community: a facility care checklist; a 
monitoring tool for motivational coaching sessions and 
for peer support sessions. In addition to this minimum 
set, sites will develop additional monitoring and process 
evaluation tools based on their needs and resources. 
Each country team does regular research site visits and 
intercountry site conference calls are held with the 
implementation teams. The information from these 
calls and from the site visits are recorded, to keep track 
of the challenges in implementation and adaptation to 
the intervention. The first participant was enrolled in 
February, April and August 2017 in Uganda, Sweden 
and South Africa, respectively.
Follow-up
Participants with T2D report back monthly (or on an 
ad hoc basis in South Africa and Sweden), for clinical 
re-evaluations and management, and medication refill. 
In cases where participants miss their study visit appoint-
ment, each country site uses the participant defaulter 
tracing approach as outlined in table 1. Participants 
report back to the health facility for follow-up evalua-
tions at month 12, at which time corresponding end-line 
measures to those described above are collected.
study outcomes
Primary outcomes
Among participants with prediabetes, the primary 
outcome of interest is overall reduction in plasma 
glucose between baseline and month 12. We hypothe-
sise that participants with prediabetes at facilities in the 
integrated care arm will on average have a higher reduc-
tion in their HbA1c reading by the end of follow-up 
compared with participants with prediabetes at facilities 
in the primary care arm (or usual care arm in Uganda).
Among participants with T2D, the primary outcome 
of interest is controlled plasma glucose levels. A partici-
pant will be classified as having had their plasma glucose 
controlled if their HbA1c reading at month 12 is <7.0%, 
or at least 2.6% below baseline reading. We hypothesise 
that among participants with T2D, the proportion with 
controlled plasma glucose in the facility plus community 
arm will be higher by the end of follow-up, compared 
with participants with controlled plasma glucose in the 
facility only arm (or usual care arm in Uganda).
Secondary outcomes
Secondary outcomes in this study include:
 ► incidence of diabetes among participants with 
pre-diabetes;
 ► incidence of adverse events, including hospitalisations 
due to hypoglycaemia- or hyperglycaemia, or compli-
cations of diabetes;
 ► behavioural outcomes, including diet, physical activity, 
foot care, tobacco and alcohol consumption;
 ► difference in out-of-pocket expenditure between 
baseline and end line and incremental (system level) 
cost of implementing the intervention;
 ► among participants with diabetes, participant satis-
faction with the diabetes treatment provided at the 
health facilities.
Sample size
Although the overall aim of the trial is to combine partic-
ipants across the three country sites, it is recognised that: 
(a) there will most likely be baseline differences across 
the country sites reflecting the different population 
characteristics between country sites and (b) site-specific 
analysis would be very relevant from a policy and poten-
tial scaleup perspective. Thus, the sample size was calcu-
lated such that differences between the trial arms can be 
detected with combined data across all the three sites in 
regard to the primary outcomes, as well as be detected at 
each study site separately. Sample size calculations were 
determined based on the primary outcome measures 
only, and on the hypothesis that by the end of follow-up, 
the integrated care arm will be superior to the primary 
care arm, and to the usual care arm in Uganda, with 
respect to the primary outcomes.
Sample size for participants with prediabetes
With the aim of being able to detect a mean difference 
of at least 3 mmol/mol HbA1c by month 12 between any 
two study arms, with a SD of 2.5 mmol/mol; the required 
sample size before adjusting for clustering at an 80% 
power and 5% level of significance is 34 participants per 
arm. For this first stage calculations, we used the formula 
as described in Hayes and Bennett15 for a continuous 
outcome.
Given the fixed number of health facilities (clusters), 
to adjust for clustering we used a formula for a fixed 
number of clusters and fixed number of participants 
within clusters as described in Hemming  et al.16 Because 
each country site is using different numbers of clusters; 
different intercluster correlation coefficient (ICC) values 
are expected. We were unable to find published literature 
providing estimates for ICC for HbA1c among persons 
with prediabetes. We therefore explored various values 
of ICC for each site, and used values that provided the 
highest sample sizes to detect the desired effect size. 
For Uganda, we used an ICC value of 0.200 to obtain a 
sample size of 112 participants, for South Africa we used 
an ICC value of 0.044 to obtain a sample size of 129 and 
for Sweden an ICC value of 0.040 to obtain a sample size 
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of 102; all per study arm. Allowing for a projected 10% 
loss to follow-up over the 12 months, the final sample size 
of participants with prediabetes per study arm is 124 for 
Uganda, 142 for South Africa and 113 for Sweden.
Sample size for participants with diabetes
Among participants with T2D, we aim at being able to 
detect a difference of at least 2% in the proportion of 
participants with diabetes with controlled plasma glucose 
by month 12 between the trial arms. The required sample 
size before adjusting for clustering at 80% power and 5% 
level of significance is 58 participants per arm. Assuming 
that in the intervention arm we shall attain reduction in 
plasma glucose per the criteria given above, in 30% of 
participants with diabetes (P1=0.3). For this first stage 
calculations, we used the formula as described in Hayes and 
Bennett15 for proportions. We found two publications of 
cluster randomised trials reporting ICC estimates among 
patient with diabetes one by Littenberg and MacLean in 
which they report an ICC for HbA1c among patients with 
diabetes of 0.05517; and another by Singh et al in which 
they report an ICC of 0.091.18 We used these estimates as 
starting values to explore various values of ICC for each 
country site, and used values that provided the highest 
sample sizes to detect the desired effect size. For Uganda, 
we used an ICC value of 0.0.091 to obtain a sample size of 
128 participants, for South Africa we used an ICC value 
of 0.020 to obtain a sample size of 136 and for Sweden an 
ICC value of 0.018 to obtain a sample size of 120; all per 
study arm. Allowing for a projected 10%; the final sample 
size of participants with diabetes per study arm is 141 for 
Uganda, 150 for South Africa and 132 for Sweden.
Figure 3 describes the trial profile, which also depicts 
the distribution of the sample size by country site, study 
arm and diagnostic category of the participants (diabetes 
and prediabetes).
data management
At each country site, research data is managed by 
trained data managers, with regular data cleaning, and 
data is uploaded quarterly into a RedCap software onto 
a server at the Sweden site via secure links. The database 
is password protected at all levels, with access only to 
authorised study staff.
Planned statistical analysis
Analyses for primary objectives
Since the unit of analysis for the primary outcome of 
interest is the individual participants, to minimise the 
effect of within cluster correlations we will employ 
generalised estimating equations,19 to evaluate changes 
over time in HbA1c values as a continuous variable 
Figure 3 SMART2D trial profile. SMART2D, Self-Management and Reciprocal learning for the prevention and management of 
Type-2-Diabetes.
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among participants with prediabetes; and the propor-
tion of participants with controlled plasma glucose 
among participants with diabetes, in relation to assigned 
trial arm. Thus, we will use multivariable linear regres-
sion mixed effects modelling with a random intercept, 
unstructured correlation matrix and robust standard 
errors, to evaluate changes over time in HbA1c, and 
logistic regression analysis to compare the proportion 
of participants with stabilised plasma glucose among 
participants with diabetes.
Analyses of secondary objectives
Appropriate statistical analysis techniques will be used 
to conduct analyses to compare secondary outcomes 
listed earlier, between the study arms. We recognise 
that since sample size calculations for this trial were not 
based on the secondary outcomes, lack of significant 
differences in analysis of secondary outcomes might 
either be true lack of differences in these outcomes, or 
due to the fact that the trial was not sufficiently powered 
to detect differences in the secondary outcomes. Thus 
interpretation of findings on secondary outcomes will 
be done with caution.
dIsCussIon
The rising burden of T2D and associated cost call for a 
multidisciplinary approach to address prevention and 
management. The SMART2D trial we are implementing 
provides an opportunity to evaluate the effectiveness 
of a set of context relevant interventions across both 
community and health facility setting in three different 
income settings. We believe that findings from this trial 
will contribute to the evidence currently needed and 
being generated,20 regarding the effectiveness of multi-
faceted approaches to the prevention and management 
of chronic illnesses like T2D. The findings may also 
clarify as to how specific components of a multifaceted 
intervention can be implemented in different contexts, 
the normalisation process for these interventions, and 
the cross-lessons from their implementation in low-in-
come, middle-income and high-income settings.
EthICs And dIssEMInAtIon
Findings from this trial will be disseminated through 
peer-reviewed publications and through local and inter-
national scientific meetings.
Author affiliations
1Department of Epidemiology and Biostatistics, School of Public Health, Makerere 
University College of Health Sciences, Kampala, Uganda
2Collaborative Care Systems Finland, Helsinki, Finland
3Chronic Disease Initiative for Africa, University of Cape Town, Cape Town, South 
Africa
4School of Public Health, University of the Western Cape, Cape Town, South Africa
5Department of Molecular Medicine and Surgery, Diabetes and Endocrine Unit, 
Karolinska Institutet, Stockholm, Sweden
6Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
7Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
8Department of Health Policy, Planning and Management, School of Public Health, 
Makerere University College of Health Sciences, Kampala, Uganda
9Department of Community Health and Behavioral Sciences, Makerere University 
School of Public Health, Kampala, Uganda
10Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 
Sweden
11Department of Learning, Informatics, Management and Ethics, Karolinska 
Institutet, Stockholm, Sweden
12Swedish Institute for Global Health Transformation, SIGHT, Royal Swedish 
Academy of Sciences, Stockholm, Sweden
13Department of Women’s and Children’s Health, The International Maternal and 
Child Health, Uppsala University, Uppsala, Sweden
14Department of Food, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden
Acknowledgements We acknowledge the institutional support of the country site 
institutions to the SMART2D consortium, and to the Sida capacity-building grant to 
Makerere University in Uganda. The SMART2D consortium includes the following 
six partner institutions: Karolinska Institutet and Uppsala University, Sweden; 
Makerere University, School of Public Health, Uganda; the University of Western 
Cape, School of Public Health, South Africa; Institute of Tropical Medicine, Belgium; 
and Collaborative Care Systems, Finland. We also acknowledge the contribution of 
the other SMART2D Study Group members: Francis Xavier Kasujja, Barbara Kirunda, 
Anthony Muyingo, Gloria Naggayi, Ronald Kusolo, Edward Ikona, Mariam Hassen, 
Mark Spires, Kululwa Ndayi, Tshilidzi Manuga, Lungiswa Tsolekile, Juliet Aweko, 
Furat Al-Murani, Dell Saulnier, Linda Timm, Aravinda Berggreen-Clausen, Douglas 
Sematimba and Jhon Rangel Alvarez. We also acknowledge the contribution of 
the participating health centers and their staff in the three sites and the local 
administration in the selected districts.
Collaborators Francis Xavier Kasujja; Barbara Kirunda; Anthony Muyingo; Gloria 
Naggayi; Ronald Kusolo; Edward Ikona; Mariam Hassen; Mark Spires; Kululwa 
Ndayi; Tshilidzi Manuga; Lungiswa Tsolekile; Juliet Aweko; Furat Al-Murani; Dell 
Saulnier; Linda Timm; Aravinda Berggreen-Clausen; Douglas Sematimba; Jhon 
Rangel Alvarez; the SMART2D Group.
Contributors DG, PA, C-GO, JOV, CJS, DS, GT, TP, SP and MD conceptualised the 
trial. DG, PA, PD, C-GO, JOV, HMA, RWM, EEK, JK, DS, TP, MD and the SMART2D 
Group are implementing the trial. DG had primary responsibility for final content. All 
authors participated in writing, read and approved the final manuscript.
Funding This study is part of the SMART2D project funded by the European 
Commission's Horizon2020 Health Coordination Activities (Grant agreement no 
643692) under call “HCO-05-2014: Global Alliance for Chronic Diseases: prevention 
and treatment of type 2 diabetes”. The Uganda site is co-funded by the Sweden 
International Development Cooperation Agency (Sida) capacity-building grant to 
Makerere University 2015-2010 Project #HS 343. The contents of this article are 
solely the responsibility of the authors and do not reflect the views of the funders of 
the SMART2D Project. 
Competing interests None declared.
Patient consent Not required.
Ethics approval Approval for conduct of this trial was obtained from the 
institutional review boards (IRB) at the respective trial country sites. In Uganda 
from the Higher Degrees, Research and Ethics Committee of Makerere 
University School of Public Health (reference number 426), in South Africa from 
the Biomedical Science Research Ethics Committee of the University of the 
Western Cape (BM/17/1/36), and in Sweden from the Regional Ethical Board in 
Stockholm (2016/2521-31/1). In Uganda, further approval was obtained from 
the Uganda National Council for Science and Technology (reference number HS 
2118).
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
group.bmj.com on March 27, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
11Guwatudde D, et al. BMJ Open 2018;8:e019981. doi:10.1136/bmjopen-2017-019981
Open Access
rEFErEnCEs
 1. WHO. WHO | Global status report on noncommunicable diseases. 
2014 http://www. who. int/ nmh/ publications/ ncd- status- report- 2014/ 
en/ (accessed 9 Dec 2015).
 2. IDF. Internationl diabetes association: Deabetes atlas. 7th Edition. 
Brussels, 2015. doi.
 3. Testa R, Bonfigli AR, Genovese S, et al. Focus on migrants with 
type 2 diabetes mellitus in European Countries. Intern Emerg Med 
2016;11:319–26.
 4. Hyman I, Gucciardi E, Patychuk D, et al. Self-management, health 
service use and information seeking for diabetes care among Black 
Caribbean immigrants in Toronto. Can J Diabetes 2014;38:32–7.
 5. Aziz Z, Absetz P, Oldroyd J, et al. A systematic review of real-world 
diabetes prevention programs: learnings from the last 15 years. 
Implement Sci 2015;10:1–17.
 6. Rawal LB, Tapp RJ, Williams ED, et al. Prevention of Type 2 
Diabetes and Its Complications in Developing Countries. A Review 
2011:121–33.
 7. WHO. Innovative care for chronic conditions: building blocks for 
action (Global Report). Geniva, 2002.
 8. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with 
chronic illness. Milbank Q 1996;74:511–44.
 9. IDF. Global Guideline for Type 2 Diabetes. International Diabetes 
Federation Guideline Development Group. Vol 104. Brussels 2014.
 10. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for 
patients with chronic illness. JAMA 2002;288:1775–914.
 11. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to 
predict type 2 diabetes risk. Diabetes Care 2003;26:725–31.
 12. Ryan RM. Deci Unwersity EL, Rochestu /. Overview of self-
determination theory: an organismic dialectical perspective. Handbok 
of self-determination, 2014:1–33.
 13. Glasgow RE, Nelson CC, Strycker LA, et al. Using RE-AIM metrics to 
evaluate diabetes self-management support interventions. Am J Prev 
Med 2006;30:67–73.
 14. Hasson H. Systematic evaluation of implementation fidelity of 
complex interventions in health and social care. Implement Sci 
2010;5:67.
 15. Hayes RJ, Bennett S. Simple sample size calculation for cluster-
randomized trials. Int J Epidemiol 1999;28:319–26.
 16. Hemming K, Girling AJ, Sitch AJ, et al. Sample size calculations for 
cluster randomised controlled trials with a fixed number of clusters. 
BMC Med Res Methodol 2011;11:102.
 17. Littenberg B, MacLean CD. Intra-cluster correlation coefficients in 
adults with diabetes in primary care practices: the Vermont Diabetes 
Information System field survey. BMC Med Res Methodol 2006;6:20.
 18. Singh J, Liddy C, Hogg W, et al. Intracluster correlation coefficients 
for sample size calculations related to cardiovascular disease 
prevention and management in primary care practices. BMC Res 
Notes 2015;8:89.
 19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and 
continuous outcomes. Biometrics 1986;42:121–30.
 20. Renders CM, Valk GD, Griffin SJ, et al. Interventions to improve the 
management of diabetes in primary care, outpatient, and community 
settings: a systematic review. Diabetes Care 2001;24:1821–33.
group.bmj.com on March 27, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
South Africa and Sweden
improve type 2 diabetes outcomes in Uganda,
integrated facility and community care to 
trial comparing facility-only care with
implementation trial: a cluster randomised 
Study protocol for the SMART2D adaptive
Meena Daivadanam
David Sanders, Göran Tomson, Thandi Puoane, Stefan Peterson and 
Mayega, Elizabeth Ekirapa Kiracho, Juliet Kiguli, Carl Johan Sundberg,
Östenson, Josefien Olmen Van, Helle Molsted Alvesson, Roy William 
David Guwatudde, Pilvikki Absetz, Peter Delobelle, Claes-Göran
doi: 10.1136/bmjopen-2017-019981
2018 8: BMJ Open
 http://bmjopen.bmj.com/content/8/3/e019981
Updated information and services can be found at: 
These include:
References
 http://bmjopen.bmj.com/content/8/3/e019981#ref-list-1
This article cites 14 articles, 2 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (460)Diabetes and Endocrinology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 27, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
